A candidate molecular signature associated with tamoxifen failure in primary breast cancer
Julie A. Vendrell(Inserm), Pascale A. Cohen(Lyon 1 Université), Agathe Bajard(Centre Léon Bérard), Alastair M. Thompson(Baylor College of Medicine), Ivan Bièche(Centre National de la Recherche Scientifique), Sylvie Chabaud(Centre de Recherche en Cancérologie de Lyon), Sirwan Hadad(University of Dundee), Colin A. Purdie(University of Dundee), Catherine Nguyen(Cooper Medical School of Rowan University), Thomas Bachelot(Centre Léon Bérard), Katherine Robertson(University of Dundee), Susan E. Bray(University of Dundee), Patrice Ravel(Inserm)
Cited by 60
Related Papers
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
|Journal of Clinical Oncology|2020|556
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
|The Lancet Oncology|2018|501